←
AnjeeDavis8,448 posts
AnjeeDavis avatar

AnjeeDavis

@AnjeeDavis

President of @FightCRC. Passionate about community engagement, patient empowerment, and social good. #crcadvocacy #CancerSurvivor 💪🏽 #RelentlessChampions

◷ Joined December 2011▧ 794 Photos and videos
Fight Colorectal Cancer avatar
⟳ AnjeeDavis retweeted
Fight Colorectal Cancer@FightCRC·Jul 1

Turn your story into action. 📣 Join our upcoming Advocacy Action Hour on July 16 at 8:30 PM ET to learn how to work with local media, write a media pitch, and amplify your advocacy beyond social media. Register now: fightcrc.org/actionhr

Post attachment
Allison Rosen, MS avatar
⟳ AnjeeDavis retweeted
Allison Rosen, MS@ARosen380·Jun 1

Always great to listen to @KimmieNgMD She discussed the Coming Wave of Early-Onset Cancer. With it on the rise we need to do more for these patients. A dedicated program can help with coordination of supportive care service like fertility preservation! @ASCO #ASCO26 @FightCRC

Post attachmentPost attachmentPost attachmentPost attachment
Manju George MVSc PhD avatar
⟳ AnjeeDavis retweeted
Manju George MVSc PhD@manjuggm·Jun 1

We all need to do more to incorporate structured exercise program as an affordable & available option to #CRC patients. Thank you for all your work! @CDNCancerTrials Dr. Chris Booth @GillSharlene #ASCO26 #CHALLENGE #CRCSM

#ASCO26 @ASCO Cost-utility analysis of #CHALLENGE trial of structured #exercise (SEP) after ACT for stage 2-3 colon cancer @CDNCancerTrials 🇨🇦 📌SEP improves DFS & OS ➡️ SEP is less costly & more effective ‘Win-Win’ ✅ ‼️We need to implement SEP into routine care 💪 #NoExcuses @JCO_ASCO 🔗 ascopubs.org/doi/10.1200/JCO…

Post attachmentPost attachmentPost attachmentPost attachment
Dr. Cathy Eng avatar
⟳ AnjeeDavis retweeted
Dr. Cathy Eng@CathyEngMD·May 31

#ASCO26 Abs LBA #3508: EPISODE-III (JCOG 1503C) randomizes ONLY stage III #coloncancer pts to ASA 100 mg x 3 yrs vs. placebo post adjuvant chemo. Primary endpoint = DFS. #cancer #cancerresearch @OncoAlert Differs vs. ALASCAA trial (Martling et al; NEJM, 2025) EPISODE-III 👉Stage III colon 👉PIK3CA MT was not required (PIK3CA MT analysis is ongoing) 👉Adjuvant therapy was required 🛑 In unselected patients, ASA 100 mg was not beneficial for DFS

Post attachment